William Rosenfeld, MD

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, provided context on improving our use of current antiseizure medications as the top priority for patients with epilepsy. [WATCH TIME: 2 minutes]

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed numerous presentations from AES 2021 that bolstered cenobamate’s known efficacy and safety profile. [WATCH TIME: 7 minutes]

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, also discussed future studies planned for cenobamate.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team saw a roughly 25% decrease in the mean use of concomitant ASMs.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team succeeded at titrating cenobamate early in the study.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team studied the interactions of ASMs and cenobamate.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team worked to reduce deleterious ASM interactions.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients with intractable epilepsy found cenobamate effective.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients found cenobamate effective for up to 43 months.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how high rates of seizure reduction were seen in treating drug resistant epilepsy.